Last reviewed · How we verify

Bevacizumab as Avastin

Mylan Pharmaceuticals Inc · Phase 3 active Biologic

Bevacizumab as Avastin is a VEGF inhibitor (monoclonal antibody) Biologic drug developed by Mylan Pharmaceuticals Inc. It is currently in Phase 3 development for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

At a glance

Generic nameBevacizumab as Avastin
SponsorMylan Pharmaceuticals Inc
Drug classVEGF inhibitor (monoclonal antibody)
TargetVEGF (Vascular Endothelial Growth Factor)
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and slows or halts tumor progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bevacizumab as Avastin

What is Bevacizumab as Avastin?

Bevacizumab as Avastin is a VEGF inhibitor (monoclonal antibody) drug developed by Mylan Pharmaceuticals Inc, indicated for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

How does Bevacizumab as Avastin work?

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

What is Bevacizumab as Avastin used for?

Bevacizumab as Avastin is indicated for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer, Glioblastoma, Metastatic renal cell carcinoma.

Who makes Bevacizumab as Avastin?

Bevacizumab as Avastin is developed by Mylan Pharmaceuticals Inc (see full Mylan Pharmaceuticals Inc pipeline at /company/mylan-pharmaceuticals-inc).

What drug class is Bevacizumab as Avastin in?

Bevacizumab as Avastin belongs to the VEGF inhibitor (monoclonal antibody) class. See all VEGF inhibitor (monoclonal antibody) drugs at /class/vegf-inhibitor-monoclonal-antibody.

What development phase is Bevacizumab as Avastin in?

Bevacizumab as Avastin is in Phase 3.

What are the side effects of Bevacizumab as Avastin?

Common side effects of Bevacizumab as Avastin include Hypertension, Proteinuria, Hemorrhage, Thromboembolic events, Gastrointestinal perforation, Wound healing complications.

What does Bevacizumab as Avastin target?

Bevacizumab as Avastin targets VEGF (Vascular Endothelial Growth Factor) and is a VEGF inhibitor (monoclonal antibody).

Related